Education
About Us
Working with TipRanks
Follow Us
Quince Therapeutics (QNCX)
NASDAQ:QNCX
QNCX Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.51 - $2.45
Previous CloseN/A
Volume30.57K
Average Volume (3M)140.28K
Market Cap
$44.53M
Enterprise Value$56.09M
Total Cash (Recent Filing)$6.21M
Total Debt (Recent Filing)$14.81M
Price to Earnings (P/E)―
Beta-0.05
Next Earnings
Aug 12, 2025EPS Estimate
-0.18Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.31
Shares Outstanding44,089,140
10 Day Avg. Volume166,067
30 Day Avg. Volume140,279
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-2.10
P/FCF Ratio0.00
Enterprise Value/Market Cap1.26
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-1.56
Forecast
1Y Price Target
$6.67Price Target Upside567.00% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
---
Quince Therapeutics News
---
Bulls Say, Bears Say
Bulls Say
Financial StabilityQuince Therapeutics has sufficient cash to fund operations into early 2026, supporting its financial stability and ongoing research and development efforts.
Innovative TreatmentThe EryDex approach allows dexamethasone to be slowly eluted from the RBCs over a month, reducing the need for daily steroids with significant side effects.
Regulatory MilestoneFDA granted SPA for the P3 NEAT trial, which is a significant regulatory milestone for the program.
Bears Say
Adverse EventsThree patients were discontinued from the study: one patient in the low-dose group had a serious adverse event (SAE) of B-cell lymphoma (unlikely treatment related) and two patients in the high-dose group had TEAEs of pyrexia and tachycardia (one patient, probably treatment related) and pain and pruritus (one patient).
Financial PerformanceQuince reported 4Q24 and 2024 results with a net loss of ($12.5M) and ($56.8M), respectively, which included $25.4M in non-cash items.
Past Clinical ChallengesThe EryDex P3 study stems from a prior miss in another P3 (ATTeST) while with EryDel, indicating previous challenges in achieving primary endpoints.
---
Ownership Overview
18.09% Insiders
3.80% Mutual Funds
3.83% Other Institutional Investors
71.21% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
QNCX FAQ
What was Quince Therapeutics’s price range in the past 12 months?
Quince Therapeutics lowest stock price was $0.51 and its highest was $2.45 in the past 12 months.
What is Quince Therapeutics’s market cap?
Quince Therapeutics’s market cap is $44.53M.
When is Quince Therapeutics’s upcoming earnings report date?
Quince Therapeutics’s upcoming earnings report date is Aug 12, 2025 which is in 121 days.
How were Quince Therapeutics’s earnings last quarter?
Quince Therapeutics released its earnings results on Mar 24, 2025. The company reported -$0.28 earnings per share for the quarter, missing the consensus estimate of -$0.18 by -$0.1.
Is Quince Therapeutics overvalued?
According to Wall Street analysts Quince Therapeutics’s price is currently Undervalued.
Does Quince Therapeutics pay dividends?
Quince Therapeutics does not currently pay dividends.
What is Quince Therapeutics’s EPS estimate?
Quince Therapeutics’s EPS estimate is -0.18.
How many shares outstanding does Quince Therapeutics have?
Quince Therapeutics has 44,089,140 shares outstanding.
What happened to Quince Therapeutics’s price movement after its last earnings report?
Quince Therapeutics reported an EPS of -$0.28 in its last earnings report, missing expectations of -$0.18. Following the earnings report the stock price went down -2.143%.
Which hedge fund is a major shareholder of Quince Therapeutics?
Currently, no hedge funds are holding shares in QNCX
---
Quince Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$6.67 (567.00% Upside)
$6.67 (567.00% Upside)
Blogger Sentiment
Bullish
QNCX Sentiment 100%
Sector Average 69%
Sector Average 69%
Crowd Wisdom
Very Negative
Last 7 Days ▼ 7.2%
Last 30 Days ▼ 1.2%
Last 30 Days ▼ 1.2%
News Sentiment
Neutral
Bullish news 50%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Positive
20 days / 200 days
Momentum
0.00%
12-Months-Change
Fundamentals
Return on Equity
-98.63%
Trailing 12-Months
Asset Growth
-29.99%
Trailing 12-Months
Company Description
Quince Therapeutics
Quince Therapeutics, Inc., a biopharmaceutical company, focuses on advancing precision therapeutics for debilitating and rare diseases. The company has discovered a broad bone-targeting drug platform to precisely deliver small molecules, peptides, or large molecules directly to the site of bone fracture and disease. Its lead compound is NOV004, an anabolic peptide engineered to precisely target and concentrate at the bone fracture site The company was formerly known as Cortexyme, Inc. and changed its name to Quince Therapeutics, Inc. in August 2022. Quince Therapeutics, Inc. was incorporated in 2012 and is headquartered in South San Francisco, California.
---
QNCX Stock 12 Month Forecast
Average Price Target
$6.67
▲(567.00% Upside)
Technical Analysis
Fate Therapeutics
―
Cara Therapeutics
―
Adaptimmune Therapeutics
―
Seres Therapeutics
―
Immunovant
―
Best Analysts Covering QNCX
1 Year
1 Year Success Rate
1/2 ratings generated profit
1 Year Average Return
-4.70%
reiterated a buy rating 19 days ago
Copying Jason Kolbert's trades and holding each position for 1 Year would result in 50.00% of your transactions generating a profit, with an average return of -4.70% per trade.
---